Axsome: Q1 Earnings Snapshot
The New York-based company said it had a loss of $1.22 per share. Losses, adjusted for non-recurring costs, came to 80 cents per share.
The results exceeded Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share.
The biopharmaceutical company posted revenue of $121.5 million in the period, which also topped Street forecasts. Eight analysts surveyed by Zacks expected $119.5 million.
Axsome shares have risen 33% since the beginning of the year. The stock has increased 50% in the last 12 months.
_____
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Should I sell my vacation home that I dream of living in when I retire to pay off $50K in credit card debt?
Total credit card debt in the US stands at $1.18 trillion this year, with 4.3% of debt in delinquency, according to the Federal Reserve Bank of New York. With these near record-high numbers, many Americans are feeling the pinch and want to find ways to dig themselves out. But should you allow your debt to disrupt your retirement plans? Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast) Want an extra $1,300,000 when you retire? Dave Ramsey says this 7-step plan 'works every single time' to kill debt, get rich in America — and that 'anyone' can do it Let's look at the example of Gavin, a 40-year-old married man with two children. He bought a home in the Caribbean in 2019 with the goal of eventually making the house his retirement home. The house is worth $400,000 now, with a $120,000 mortgage balance. Unfortunately, the mortgage loan has a variable interest rate, which is currently at 10.5% with no possible options for refinancing. The home currently generates $700 per month in profit as a short-term rental, but makes less during off off-season and managing it is stressful. Worse, the neighborhood may soon prohibit short-term rentals in the area, so that would be the end of this revenue stream. Additionally, Gavin might also be on the hook for local property taxes and, as a foreign investor, other possible fees and taxes too. On top of this, the buyer is a renter in the US where he currently lives and he has $50,000 in credit card debt. Does it make sense for him to sell the vacation property to pay off what he owes? He's considering buying a home locally and using the rest of the money to invest, build up an emergency fund, or start a college fund for his kids. Selling the vacation home could be a great solution Selling the vacation home in this particular case seems like an easy answer. While it is currently generating a small profit, earning $8,400 per year on a $400,000 asset isn't a great return, especially given the hassle of being the host and the substantial interest he is paying on his mortgage. But losing the short-term rental income would be a major downside. Read more: Nervous about the stock market? Gain potential quarterly income through this $1B private real estate fund — even if you're not a millionaire. Aside from the poor ROI of the home, the interest on $50,000 in credit card debt that he currently has is an absolute financial killer, given that the average credit card interest rate is 21.16% as of May 2025. The $700 per month he is earning from his rental most likely is not even enough to cover the interest that his credit card debt accrues each month. With a home worth $400,000, and assuming closing costs are around 4% (the average is 2% to 5%), this homeowner would still end up with about $384,000 after paying for the transaction fees from the sale of the home. Now, since the home isn't his primary home, it's possible he could owe capital gains taxes if his profits exceeded $250,000 as a single person or $500,000 as a married joint filer. However, since Gavin is married and the home isn't netting in excess of $500,000, he'd likely be spared this tax. He may also need to pay additional sales taxes to the government of his host country. If he doesn't, he could pay off the $120,000 still remaining on the mortgage he owes, as well as his $50,000 in credit card debt and still walk away with around $214,000. That would be a good start to make a down payment on a home in the US for his family (in which he can retire), or to start investing for his future. He could save for his two kids to go to college, start an emergency fund and best of all, free up a lot of income by eliminating his credit card debt and the interest he would be paying on that into the future. In fact, if he uses the money wisely, he could not only set himself up for financial stability, but he could also choose to save to buy another retirement home down the road, when it makes more financial sense. Are there downsides to selling? While Gavin's circumstances make a strong case for selling the home, it's worth looking at whether there are any downsides to doing so, beyond losing the $700 in rental income. Since the home he owns doesn't have a great mortgage, isn't generating a big profit and there's no reason to believe it is a one-of-a-kind home, there's very little downside in cashing out now and using the proceeds to create some more financial stability. The only real risk would be that real estate values skyrocket in his chosen Caribbean retirement destination. This would either price him out of buying his dream retirement home later on or prevent him from earning more on the possible future sale of his vacation home. However, it's unlikely the ROI on Caribbean real estate would exceed the returns he'd get by investing in the stock market in the states or that the increase in the value would be worth paying the interest on the credit card debt and the mortgage combined. There are likely wiser ways to make that money work. So, if he's investing wisely over time, he should likely be able to buy a comparable home as a retiree if he wants to. He could also end up changing his retirement plans if he decides he'd rather stay in the US and be close to his potential grandchildren — and if that happens, it would have been a poor investment to pay for a house that's costly to keep only to end up not retiring there anyway. Selling now with the chance to rebuy later seems like a much better bet. In fact, all signs point to the fact that selling the home seems like the best move in this situation and it could be the start of a much more financially secure — and less stressful — future. What to read next Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Here are 5 simple ways to grow rich with real estate if you don't want to play landlord. And you can even start with as little as $10 Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
Associated Press
2 hours ago
- Associated Press
Faruqi & Faruqi Reminds Centene Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 8, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Centene To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Centene between December 12, 2024 and June 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Centene Corporation ('Centene' or the 'Company') (NYSE: CNC) and reminds investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors began to question the veracity of defendants' public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of the Company's marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75. Following this news, Centene's common stock declined dramatically, from a closing market price of $56.65 per share on July 1, 2025, Centene's stock price fell to $33.78 per share on July 2, 2025, a decline of 40.4%. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Centene's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Centene Corporation class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Associated Press
2 hours ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Novo Nordisk securities during the Class Period. A copy of the Complaint can be obtained at [Click here for information about joining the class action] On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025. The Company attributed the reduction to 'lowered growth expectations for the second half of 2025' for both Wegovy and Ozempic due to 'the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.' On this news, Novo Nordisk's American Depositary Receipt ('ADR') price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980
